LearnGlossaryMarketStocksSuperinvestorsSign in

PLSE

Pulse Biosciences, Inc.

Healthcare · $3.5B market cap

Verdict

We can't put a fair value on PLSE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-10.9% a year✗
Sales growth-29.5% a year✗
Free cash flow growth—?
Return on invested capital-70.9%✗

Follow PLSE

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: 2 open-market purchases worth $100K. Why purchases matter

Purchases

Teplitsky Liane Rae

Chief Operating Officer · 2026-09-01

Bought

$50K

Teplitsky Liane Rae

Chief Operating Officer · 2026-08-31

Bought

$50K

About Pulse Biosciences, Inc.

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target…

Medical - Instruments & Supplies

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works